Figure 6
TWIST cytoplasmic/nuclear (cyt./nuc.) expression/location and FOSL1 (Fra-1) expression in human melanoma are correlated with patient survival. (A) Kaplan-Meier overall-survival analysis (OS): TWIST expression in melanoma samples was visualized by TWIST specific immunohistochemistry in melanoma samples from 106 patients. Patients were grouped as TWIST cyt./nuc. low (cyt./nuc. TWIST ≤ 2) or TWIST high (cyt./nuc. TWIST > 2). TWIST cyt./nuc. low (≤2) show a significantly longer overall survival than TWIST cyt./nuc. high (>2) patients (p = 0.010). (B) A melanoma with high TWIST cyt./nuc. expression: Immunohistochemical staining of paraffin embedded patient tissue for TWIST. (C) A melanoma with low TWIST cyt./nuc. expression: Immunohistochemical staining of paraffin embedded patient tissue for TWIST. Arrows indicate highly TWIST positive nuclei in normal skin epidermis. (D) Kaplan-Meier overall-survival analysis (OS): FOSL1 expression in melanoma samples was visualized by FOSL1 specific immunohistochemistry in melanoma samples from 106 patients. Patients were grouped as FOSL1 0–1 (no or low FOSL staining) or FOSL1 2–3 (medium or high FOSL1 staining). FOSL1 low patients show a significantly longer overall survival than FOSL high patients (p = 0.023). (E) A melanoma with high FOSL1 expression: Immunohistochemical staining of paraffin embedded patient tissue for FOSL1. (F) A melanoma with low FOSL1 expression: Immunohistochemical staining of paraffin embedded patient tissue for FOSL1.
